The PTP1B selective inhibitor MSI-1436 mitigates Tunicamycin-induced ER stress in human hepatocarcinoma cell line through XBP1 splicing modulation

PLoS One. 2023 Jan 17;18(1):e0278566. doi: 10.1371/journal.pone.0278566. eCollection 2023.

Abstract

Protein tyrosine phosphatase PTP1B is considered as a key metabolic enzyme that has been reported to be associated with insulin resistance onset, and underlying cellular metabolic malfunctions, including ER stress and mitochondrial failure. In this study, effects of selective PTP1B inhibition using MSI-1436 on cellular apoptosis, oxidative stress, mitochondrial dysfunction and ER stress have been assessed using an in vitro model of Tunicamycin induced ER stress in HepG2 cell line. Inhibition of PTP1B using MSI-1436 significantly increased cell viability and reduced the number of apoptotic cells as well as the expression of key apoptosis initiators and effectors. MSI-1436 further mitigated ER stress, by downregulating the expression of IRE1, ATF6 and PERK transcripts, all being key ER stress sensors. Interestingly, MSI-1436 inhibited the XBP1 splicing, and thus its UPR-associated transcriptional activity. PTP1B inhibition further enabled to restore proper mitochondrial biogenesis, by improving transmembrane potential, and diminishing intracellular ROS while restoring of endogenous antioxidant enzymes genes expression. PTP1B inhibition using MSI-1436 could improve cellular apoptosis and metabolic integrity through the mitigation of ER and mitochondrial stress signalling pathways, and excessive ROS accumulation. This strategy may be useful for the treatment of metabolic disorders including IR, NAFLD and diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis*
  • Cell Line
  • Endoplasmic Reticulum Stress*
  • Humans
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1* / antagonists & inhibitors
  • RNA Splicing
  • Reactive Oxygen Species / pharmacology
  • Signal Transduction*
  • Tunicamycin / pharmacology
  • X-Box Binding Protein 1* / genetics

Substances

  • Reactive Oxygen Species
  • Tunicamycin
  • X-Box Binding Protein 1
  • XBP1 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1

Grants and funding

The research work has been supported by the National Science Centre in Poland over the course of the realization of the projects: ‘Inhibition of tyrosine phosphatase as a strategy to enhance insulin sensitivity through activation of chaperone mediated autophagy and amelioration of inflammation and cellular stress in the liver of equine metabolic syndrome (EMS) horses.’ (2018/29/B/NZ7/02662). - Publication fees have been supported by the Leading Research Groups support project from the subsidy increased for the period 2020–2025 in the amount of 2% of the subsidy referred to Art. 387 (3) of the Law of 20 July 2018 on Higher Education and Science, obtained in 2019” from the Wrocław University of Experimental and Life Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors “Sai Santosh Babu Komakula and Nabil Adrar” received a Postdoctoral salary from the research project financed by the National Science Centre in Poland, 2018/29/B/NZ7/02662.